ArticleCardiology research2026
Association of Circulating Brain-Derived Neurotrophic Factor With Coronary Risk Factors and Coronary Artery Disease in Patients Who Have Undergone Coronary Computed Tomography Angiography.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have reported low circulating brain-derived neurotrophic factor (BDNF) concentrations in patients with coronary artery disease (CAD), but findings have been inconsistent and may be influenced by platelet-related factors. This study evaluated the association between plasma BDNF and CAD in patients undergoing coronary computed tomography angiography (CCTA). Methods: We prospectively enrolled 402 consecutive patients who underwent CCTA for CAD screening at Fukuoka University Hospital and who were either clinically suspected of having CAD or had at least one cardiovascular risk factor. CAD was defined as coronary artery stenosis of 50% or greater. Plasma BDNF was measured and its association with CAD and clinical variables was examined using multivariate linear regression and logistic regression. The effect of covariate adjustment on the association between BDNF and CAD was assessed using the change-in-estimate method. Results: Patients with CAD (n = 186) had lower plasma BDNF levels compared with patients without CAD (n = 216) (5.73 ± 3.16 vs. 6.41 ± 3.42 ng/mL, P = 0.039). Multivariate linear regression analysis revealed that platelet count was the strongest determinant of plasma BDNF levels (β = 0.027, P < 0.001). Unadjusted logistic regression analysis showed that higher BDNF levels were associated with a lower prevalence of CAD (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.88-1.00, P = 0.039). However, after adjusting for platelet count, this association weakened and became non-significant (OR 0.976, 95% CI 0.909-1.05, P = 0.49). Further adjustment for age and coronary artery calcification score did not significantly alter the results. Conclusions: In a cohort undergoing CCTA with a relatively intermediate pre-test probability of CAD, plasma BDNF levels were lower in patients with CAD, but this crude correlation was primarily explained by platelet-related confounding factors. Platelet count should be considered when evaluating BDNF as a cardiovascular biomarker in patients with intermediate cardiovascular risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.